Hui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hui Liu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Dapeng Li
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
14 shared publications - Feng Shi
Hunan Cancer Hospital 1 , Changsha, China
14 shared publications - Jianwu Qin
Department of Thyroid Head and Neck Surgery, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
14 shared publications - Jiewu Zhang
10Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China
14 shared publications - Ming Gao
Department of Thyroid and Breast Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, China
14 shared publications - Minghua Ge
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
14 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
(A) Kaplan–Meier estimate of progress-free survival (PFS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 3 months before enrollment. (C) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 12 months before enrollment. The tick marks indicate censored data.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
(A) Kaplan–Meier estimate of progress-free survival (PFS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 3 months before enrollment. (C) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 12 months before enrollment. The tick marks indicate censored data.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Grade 3 or above treatment-related adverse events (TRAEs)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Grade 3 or above treatment-related adverse events (TRAEs)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Multivariable Cox regression analysis of determinants of PFS
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Multivariable Cox regression analysis of determinants of PFS
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
(A) The Kaplan-Meier curve of overall survival (OS) in the per protocol set. (B) The Kaplan-Meier curve of OS adjusted by a two-stage estimation method based on the rank preserving structural failure time (RPSFT) model. The tick marks indicate censored data.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
(A) The Kaplan-Meier curve of overall survival (OS) in the per protocol set. (B) The Kaplan-Meier curve of OS adjusted by a two-stage estimation method based on the rank preserving structural failure time (RPSFT) model. The tick marks indicate censored data.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
The Kaplan-Meier curve of progress-free PFS in the Per-Protocol Set. The tick marks indicate censored data.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
The Kaplan-Meier curve of progress-free PFS in the Per-Protocol Set. The tick marks indicate censored data.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 months before enrollment. (C) Kaplan–Meier estimate of OS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 12 months before enrollment. The tick marks indicate censored data.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 months before enrollment. (C) Kaplan–Meier estimate of OS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 12 months before enrollment. The tick marks indicate censored data.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Multivariable Cox regression analysis of determinants of OS (without consideration of crossover)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Multivariable Cox regression analysis of determinants of OS (without consideration of crossover)